BR112018008684A2 - injectable botulinum toxin formulations and processes of long-term use of the therapeutic or cosmetic effect - Google Patents

injectable botulinum toxin formulations and processes of long-term use of the therapeutic or cosmetic effect

Info

Publication number
BR112018008684A2
BR112018008684A2 BR112018008684-3A BR112018008684A BR112018008684A2 BR 112018008684 A2 BR112018008684 A2 BR 112018008684A2 BR 112018008684 A BR112018008684 A BR 112018008684A BR 112018008684 A2 BR112018008684 A2 BR 112018008684A2
Authority
BR
Brazil
Prior art keywords
botulinum toxin
positively charged
treatment
gly
duration
Prior art date
Application number
BR112018008684-3A
Other languages
English (en)
Portuguese (pt)
Inventor
L. Ruegg Curtis
M. Waugh Jacob
Original Assignee
Revance Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58630886&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112018008684(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Revance Therapeutics, Inc. filed Critical Revance Therapeutics, Inc.
Publication of BR112018008684A2 publication Critical patent/BR112018008684A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0059—Cosmetic or alloplastic implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
BR112018008684-3A 2015-10-29 2016-10-28 injectable botulinum toxin formulations and processes of long-term use of the therapeutic or cosmetic effect BR112018008684A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562248255P 2015-10-29 2015-10-29
US62/248,255 2015-10-29
PCT/US2016/059492 WO2017075468A1 (en) 2015-10-29 2016-10-28 Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Publications (1)

Publication Number Publication Date
BR112018008684A2 true BR112018008684A2 (en) 2018-11-27

Family

ID=58630886

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008684-3A BR112018008684A2 (en) 2015-10-29 2016-10-28 injectable botulinum toxin formulations and processes of long-term use of the therapeutic or cosmetic effect

Country Status (16)

Country Link
US (2) US20180311333A1 (https=)
EP (1) EP3368071B1 (https=)
JP (2) JP6955491B2 (https=)
KR (1) KR102794108B1 (https=)
CN (1) CN109069608A (https=)
AU (2) AU2016343748A1 (https=)
BR (1) BR112018008684A2 (https=)
CA (1) CA3003447A1 (https=)
CO (1) CO2018005361A2 (https=)
DK (1) DK3368071T3 (https=)
ES (1) ES2907652T3 (https=)
IL (2) IL259016A (https=)
MX (1) MX2018005256A (https=)
RU (1) RU2018119765A (https=)
SG (2) SG11201803566TA (https=)
WO (1) WO2017075468A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG160357A1 (en) * 2005-03-03 2010-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
PH12012500549A1 (en) * 2009-10-21 2017-08-23 Revance Therapeutics Inc Methods and systems for purifying non-complexed botulinum neurotoxin
AU2016343748A1 (en) 2015-10-29 2018-05-17 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect
AU2017360346B2 (en) 2016-11-21 2023-11-23 Eirion Therapeutics, Inc. Transdermal delivery of large agents
JP7604222B2 (ja) * 2017-03-22 2024-12-23 ボンチ インコーポレイテッド 治療用のボツリヌス神経毒素
MX2019013716A (es) 2017-05-18 2020-10-12 Revance Therapeutics Inc Métodos de tratamiento para la distonía cervical.
EP3641746B1 (en) 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection
EP3675900A4 (en) 2017-08-28 2021-05-05 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP3703738A4 (en) * 2017-11-03 2021-09-08 ReVance Therapeutics, Inc. BOTULINIC TOXIN FORMULATIONS AND METHODS OF USE THEREOF IN PLANTARY FASCIITIS, WITH EXTENDED DURATION OF EFFECT
SG11202005239YA (en) * 2017-12-04 2020-07-29 Revance Therapeutics Inc Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
AU2019337656A1 (en) * 2018-09-13 2021-05-06 Allergan, Inc. Methods for treatment of masseter muscle hypertrophy
CA3139983A1 (en) * 2019-05-14 2020-11-19 Eirion Therapeutics, Inc. Delaying peak effect and/or extending duration of response
US20230210963A1 (en) * 2020-03-18 2023-07-06 Revance Therapeutics, Inc. Injectable botulinum toxin methos for treating headaches
KR102397708B1 (ko) * 2020-04-29 2022-05-16 한국화학연구원 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물
KR102324855B1 (ko) * 2020-05-20 2021-11-11 오스템임플란트 주식회사 보툴리눔 독소를 포함하는 약제학적 액상 조성물
KR20230086752A (ko) * 2020-10-13 2023-06-15 레반스 테라퓨틱스, 아이엔씨. 경부 근긴장이상증의 치료 방법
KR102266384B1 (ko) * 2021-01-25 2021-06-21 주식회사 울트라브이 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제
US20250268996A1 (en) * 2021-02-21 2025-08-28 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
US20240216487A1 (en) * 2021-04-26 2024-07-04 Shanghaitech University Intramuscular compositions of botulinum neurotoxins
WO2023085849A1 (ko) * 2021-11-15 2023-05-19 (주)메디톡스 보툴리눔 독소 조성물
EP4537850A1 (en) * 2022-06-10 2025-04-16 Medytox Inc. Composition for stabilizing botulinum neurotoxin, botulinum neurotoxin formulation containing same, and polypeptides for use therein
KR102714765B1 (ko) * 2023-05-04 2024-10-11 주식회사 파마리서치바이오 Dna 단편 혼합물 및 보툴리눔 독소를 포함하는 보툴리눔 독소의 생체 내 지속성이 증가된 지속성 제제
WO2025064729A1 (en) * 2023-09-19 2025-03-27 Revance Therapeutics, Inc. Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6444209B1 (en) 1996-10-28 2002-09-03 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
ATE519494T1 (de) 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
DE10043982A1 (de) * 2000-09-05 2002-03-14 Armin Maurer Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
AU2009332947C1 (en) 2008-12-31 2019-01-03 Revance Therapeutics, Inc. Injectable botulinum toxin formulations
EP2445521A4 (en) 2009-06-25 2015-08-26 Revance Therapeutics Inc ALBUMINE-FREE BOTULINUM TOXIN FORMULATIONS
PT2661276T (pt) * 2011-01-07 2017-10-06 Revance Therapeutics Inc Composição tópica que inclui uma tóxina botulínica e um corante
AU2013234988A1 (en) 2012-03-22 2014-10-09 Revance Therapeutics, Inc. Method of treatment of wrinkles using topical chemodenervating agents
CA2889833A1 (en) * 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and methods for safe treatment of rhinitis
AU2016343748A1 (en) 2015-10-29 2018-05-17 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
SG11201803566TA (en) 2018-05-30
KR20180077202A (ko) 2018-07-06
RU2018119765A3 (https=) 2020-03-17
JP2018531984A (ja) 2018-11-01
ES2907652T3 (es) 2022-04-25
AU2023241373A1 (en) 2023-10-26
SG10202004337WA (en) 2020-06-29
AU2016343748A1 (en) 2018-05-17
JP6955491B2 (ja) 2021-10-27
CO2018005361A2 (es) 2018-10-10
US20180311333A1 (en) 2018-11-01
MX2018005256A (es) 2019-09-04
CN109069608A (zh) 2018-12-21
IL259016A (en) 2018-06-28
EP3368071B1 (en) 2022-01-26
DK3368071T3 (da) 2022-05-02
IL286472A (en) 2021-10-31
CA3003447A1 (en) 2017-05-04
KR102794108B1 (ko) 2025-04-11
US20220062400A1 (en) 2022-03-03
EP3368071A1 (en) 2018-09-05
RU2018119765A (ru) 2019-12-02
WO2017075468A1 (en) 2017-05-04
EP3368071A4 (en) 2019-05-29
JP2022008814A (ja) 2022-01-14
NZ742018A (en) 2024-07-05

Similar Documents

Publication Publication Date Title
US20220062400A1 (en) Injectable Botulinum Toxin Formulations And Methods Of Use Thereof Having Long Duration Of Therapeutic Or Cosmetic Effect
US20240058628A1 (en) Injectable botulinum toxin formulations
US20250064905A1 (en) Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration
HK1256878B (en) Injectable botulinum toxin formulations
HK40000453A (en) Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]